Aprea’s executive management team, Board of Directors and scientific founders are unified by their dedication to developing groundbreaking, precision therapeutics for patients with genetically defined cancers. Our team’s exceptional qualifications and deep expertise have accelerated Aprea’s mission and continue to fuel its growth as a leader in DDR-targeted therapeutics.
President and Chief Executive Officer
Oren Gilad, Ph.D., has served as Chief Executive Officer since July 2022 and as President and a member of our Board of Directors since May 2022. He previously served as President and CEO of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. He brings extensive experience across multiple phases of drug development. Prior to founding Atrin in 2011, Dr. Gilad authored several high impact scientific publications over the course of a 13-year academic career, including demonstration of the importance of the ATR pathway in cancer development and treatment. Dr. Gilad holds a Ph.D from University of California at Davis and a B.Sc from the Hebrew University.
Senior Vice President and Chief Financial Officer
John joined Aprea in January 2023 from Windtree Therapeutics where he served as Senior Vice President and Chief Financial Officer since 2020. He brings more than 30 years of financial leadership experience in the pharmaceutical, biopharmaceutical, and clinical research sectors. He brings broad-based experience in financial, administrative, information technology, and facility functions, in addition to successfully completing IPO and follow-on offerings for several pharmaceutical companies. John has also recently provided consulting services to various life science companies, headed up finance at Trevena, Inc., where he was instrumental in successfully raising equity; NephroGenex, Inc., where he actively led the IPO and subsequent financial restructuring and sale of the company; Savient Pharmaceuticals, where he led a sale process resulting in $120 million in proceeds; and PharmaNet where he successfully completed its sale for approximately $250 million, which then became known as PharmaNet Development Group, where he directed financial and administrative operations for the company. John received a B.S. in Accounting and Business and Computer Science from DeSales University and is a certified public accountant.
Chief Business Advisor
Ze’ev Weiss, CPA, B.Sc., has served as our Chief Business Advisor since May 2022. Ze’ev brings over 20 years of broad and extensive biopharmaceuticals industry experience in strategic, operational, and corporate development in the emerging and established healthcare industry. He previously served as Chief Business Officer of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea. Until 2017, Ze’ev served as the CEO and formerly as Executive VP Commercial Operations of Intec Pharma (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill® platform technology. He successfully led Intec’s IPO on NASDAQ as well as multiple collaboration agreements with global leading pharmaceutical companies. Ze’ev also had a central role in leading Intec from their very early stage into late clinical stage, including financing, pre-clinical and clinical development, regulatory and intellectual property activities. Prior to Intec, Ze’ev was Head of Life Sciences Strategic Consulting at PricewaterhouseCoopers, Israel. At PwC, he led numerous corporate developments, business development, strategic planning and corporate finance consulting engagements with various healthcare companies. Ze’ev holds a BA in accounting and is a certified public accountant. He also earned a B.Sc in Biology and has completed M.Sc. in Neuro-Biochemistry studies from Tel Aviv University, Israel.
Senior Medical Advisor
Nadeem Mirza, M.D., M.P.H. has served as Senior Medical Advisor to Aprea since February 2023. Dr. Mirza brings over 30 years of clinical and developmental experience in solid tumors and hematologic malignancies. He currently serves as Senior Vice President, Clinical Development at Salarius Pharmaceuticals and previously served as Chief Medical Advisor at TRIGR Therapeutics developing bispecific antibodies. Prior to that, Dr. Mirza served as Senior Vice President, Corporate Medical Affairs at Verastem Oncology where he oversaw the launch of Copiktra®. Prior to Verastem, he served as Global Head Hematology and Solid Tumors at Abbvie Oncology where he oversaw the global launch of Venclexta®. Before Abbvie, he was Vice President, Head of Oncology, North America Medical Affairs at Sanofi Oncology where he was responsible for medical affairs programs to support 12 products across several oncology indications. Dr. Mirza has also held leadership roles in medical affairs and clinical development at Genzyme/Sanofi, Onyx Pharmaceuticals, Abraxis Oncology and Berlex Oncology. He holds an M.P.H. from the University of Texas at Houston, and earned his M.D. from the University of Punjab.
Translational Medicine Advisor
Dr. Carleton joins Aprea with over 20 years of experience in the pharmaceutical/biotech industry where he has held leadership roles in preclinical and clinical drug development. He most recently served as Vice President of Translational Medicine at Inipharm where the team developed an inhibitor to the oxidoreductase HSD17B13 for treatment of liver disease. Prior to that, he was Vice President of Translation Medicine at Mavupharma until Abbvie’s acquisition of Mavu and its ENPP1 inhibitor program. As Director of Translational Medicine at Bristol Myers Squibb, Dr. Carleton led clinical oncology biomarker development for the anti-CSF1R (Cabiralizumab) and anti-IL8 (BMS-986253) programs for which his team established elevated serum IL-8 is associated with reduced clinical benefit to immune checkpoint blockade. Dr. Carleton also led research groups at Presage Biosciences, Matrix Genetics, and Rosetta Inpharmatics, a fully owned subsidiary of Merck. Within the Merck oncology franchise, Dr. Carleton was the biomarker lead for Merck’s WEE1 inhibitor (MK-1775) and its PARP inhibitor programs prior to their out licensing to AstraZeneca (AZD1775, Adavosertib) and Tesaro (Niraparib). Dr. Carleton obtained his Ph.D. in microbiology from the University of Texas at Austin, was a CRI postdoctoral fellow, Arthritis Young Investigator, and currently serves part time as Senior Scientific Director at The Mark Foundation for Cancer Research.